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the original work isObjective: Adolescent and young adult (AYA) populations (12–24 years) represent
over 40% of new HIV infections globally. Adolescence is sometimes characterized by
high-risk sexual behaviour and a lack of engagement with healthcare services that can
affect adherence to antiretroviral therapy (ART). Despite adherence to ART being
critical in controlling viral replication, maintaining health and reducing onward viral
transmission, there are limited data on ART adherence amongst AYA globally. We
undertook a systematic review and meta-analysis of published studies reporting
adherence to ART for AYA living with HIV.
Design and methods: Searches included Embase, Medline and PsychINFO databases
up to 14 August 2013. Eligible studies defined adequate adherence as at least 85% on
self-report or undetectable blood plasma virus levels. A random effects meta-analysis
was performed and heterogeneity examined using meta-regression.
Results: We identified 50 eligible articles reporting data from 53 countries and 10 725
patients. Using a pooled analysis of all eligible studies, 62.3% [95% confidence interval
(CI) 57.1–67.6; I2 : 97.2%] of the AYA population were adherent to therapy. The lowest
average ART adherence was in North America [53% (95% CI 46–59; I2 : 91%)], Europe
[62% (95% CI 51–73; I2 : 97%)] and South America [63% (95% CI 47–77; I2 : 85%]
and, with higher levels in Africa [84% (95% CI 79–89; I2 : 93%)] and Asia [84% (95% CI
77–91; I2 : 0%].
Conclusion: Review of published literature from Africa and Asia indicate more than
70% of HIV-positive AYA populations receiving ART are adherent to therapy and lower
rates of adherence were shown in Europe and North America at 50–60%. The global
discrepancy is probably multifactorial reflecting differences between focused and
generalised epidemics, access to healthcare and funding.
 2014 Wolters Kluwer Health | Lippincott Williams & WilkinsAIDS 2014, 28:1945–1956Keywords: adolescence, antiretroviral therapy, highly active, HIV, medication
adherence, patient compliance, young adultIntroduction
Into the third decade of the HIV/AIDS epidemic, there
are 34 million people living with HIV in the world,
of whom five million are aged between 15 and 24 years
[1]. Adolescence is a period of mental, physical and
emotional maturation wherein commonly individuals
undergo behavioural experimentation, identity forma-
tion, risk taking and face difficult choices on roman-
tic relationships, sexual behaviour and alcohol andippincott Williams & Wilkins. Unaut
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properly cited.recreational drug use [2,3]. Furthermore, young people
often have poorly developed life skills and are often
lacking in worldly knowledge and financial autonomy
[4]. They also have limited access to health facilities and
are prone to sexual coercion and peer pressure [4].
Adolescents have been described as the ‘fulcrum’ and the
‘centre of the epidemic’ [5], with 42% of new HIV
infections occurring in this age group in 2010 [1]. For
all of these reasons, adolescents have been frequently
recognized as a vulnerable group to becoming infectedhorized reproduction of this article is prohibited.
f Public Health, and cCommunicable Diseases Section,
ol of Public Health, Norfolk Place, London W2 1PG, UK.
: 24 April 2014.
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1946 AIDS 2014, Vol 28 No 13and to being marginalized from mainstream healthcare
provisions [6].
Despite the dramatic improvement in survival and
marked reduction in transmission through antiretroviral
therapy (ART), a sustained effect depends on high levels
of adherence (>95%) to daily oral dosing [7,8]. Poor ART
adherence increases the risk of viral drug-resistance, limits
treatment efficacy, leading to disease progression, and
reduces future therapeutic options [9] as well as increasing
the risk of transmission due to unsuppressed viral
replication [10].
Following the publication of the HPTN052 study [10]
and the accompanying paradigm shift in HIV prevention
approaches to using ART strategically for all people living
with HIV to significantly reduce the risk of onward viral
transmission, successful viral suppression amongst core
risk-taking groups, which include Adolescent and young
adult (AYA) living with HIV, has a renewed focus.
Mathematical models have explored the potential
elimination of HIV transmission with a universal HIV
testing approach accompanied by immediate ART for all
HIV-positive individuals, but this must include AYA if
it is to confer a population-level effect. The few studies
on adherence show that access to antiretroviral and
adherence is lower in adolescents than in the adult
population [11–16]. There has been one previous review
of ARTadherence among HIV-infected youth [2], which
showed adherence rates ranging from 28.3 to 69.8% in the
USA. This review aims to update the findings of the
previous review and quantifying adherence in AYA at a
global level.Materials and methods
Search strategy and selection criteria
We followed the PRISMA guidelines in carrying out this
research [17]. Articles were identified through searches
conducted on Medline, Embase, HMIC, Maternity and
Infant Care, and PsychINFO up to 14 August 2013 using
combinations of keywords such as ‘adolescent’, ‘young
adult’, ‘adherence’, ‘patient compliance’, ‘antiretroviral
therapy’ and ‘antiretrovirals’ as MESH headings and free-
text terms. Bibliographies of potentially eligible full-text
publications were also searched and when necessary,
authors of relevant studies were contacted for clarification
and for additional information. Potentially eligible studies
were downloaded into EndNote, and titles and abstracts
were searched according to the predefined inclusion and
exclusion criteria.
We included quantitative studies reporting original data
on medication adherence among HIV-infected youth
(ages 12–24 years). Studies that included participants
outside this age range were included where the median
age of participants fell within the 12–24 year range.pyright © Lippincott Williams & Wilkins. UnauthoStudies were included if adherence was measured
by subjective measurement (self-reported adherence),
pharmacologic measurements (pill count, pharmacy refill
records) or physiological methods (viral suppression).
Despite being a subjective measure, self-report is non-
invasive, easy to administer and has been shown to correlate
with objective measures such as pill counts [18,19].
Although viral load is an indirect measure, many studies
have indicated that high adherence (>95%) is needed to
maintain adequate virologic suppression [20–22].
Studies were included if they defined adherence as 100%,
more than 95%, more than 90% and more than 85% of the
medication taken correctly for a defined period in the
study, or viral suppression as the lower limit detectable at
the time and location defined by the authors (range <50
to <500 copies/ml). The studies also had to show the
proportion of their population that was adequately
adherent according to the study definition rather than
reporting mean adherence. All study designs were
included except for guidelines, reviews and case studies.
The length of follow-up was left undefined and the
studies were only considered if published after 1996
(the designated start of highly active ART era). Only
English publications were included. Finally, studies were
excluded if the population was deemed unrepresentative
of the general adolescent population living with HIV
(e.g. containing experimental interventions to promote
adherence, financial incentives).
Study selection and data extraction
Two investigators (S.K., S.M.G.) conducted the search,
reviewed all abstracts and full-text articles independently,
with final inclusion decided through consensus with
verification with senior study authors when needed. We
extracted the data independently and in duplicate. The
country, study year, sample size, age, sex, methods of
adherence measurement and outcomes were extracted
fromeach study.Whenmore than one adherencemeasure-
ment was used, data on all measures were extracted and the
most objective method was chosen for the analysis (e.g.
viral suppression). When a study examined the effect of an
intervention onmedication adherence, only the adherence
data for the control group were extracted and analysed.
Informationon disease state, type of antiretroviral regimen,
the time the individuals were on treatment for and socio-
economic status were not abstracted due to large
heterogeneity of each study population. For all studies,
ARTwas taken as potent standard triple therapy.
Data analysis
Point estimates and Clopper–Pearson confidence inter-
vals (CIs) [23] were calculated and the transformed data
were pooled using DerSimonian–Laird [24] random
effects model, as large heterogeneity was anticipated
considering the varied populations, healthcare systems
and the nature of the epidemic. We explored potential
sources of heterogeneity with univariate, random-effectsrized reproduction of this article is prohibited.
Meta-analysis adherence to antiretroviral therapy in adolescents Kim et al. 1947meta-regression using continents, measures of adherence,
thresholds of adherence, percentage of women in the
study, study year (pre-2005 and 2005 onwards) and age of
participants (<20 vs.  20years) as variables because they
were identified as potential factors that might explain the
heterogeneity observed in the analysis. We did analyses
using Stata version 11 [25].
Forest plots were created for each region that showed
individual study proportions meeting the threshold for
appropriate adherence (as defined by the original study)
with Clopper–Pearson CIs, the overall DerSimmonian–
Laird pooled estimate and the I2-value for heterogeneity.
Results are reported as combined adherence proportions
with 95% CIs.Results
Fifty-one studies published between 1999 and 2013
passed the full-text screening and reported adherence
rates for 10 725 patients in 53 countries. Seven studies
were reported in national or international conference
abstracts [26–30]; the rest as full-text articles. A flow
diagram of studies included in the analysis is detailed in
Fig. 1, with characteristics displayed in Table 1 [31–73]
grouped by geographical region. Studies reported similar
thresholds for adherence monitoring (e.g. 100%, >95%,
>90% and >85%) and viral suppression was most
commonly defined as less than 400 copies/ml. Pooled
adherence rates across all studies are summarized inCopyright © Lippincott Williams & Wilkins. Unaut
1125 records identified
through database
searching  
666 records after duplicates removed
634 abstracts screened  
198 of full-text articles assessed for
eligibility 
50 studies included in quantitative
analysis 
Fig. 1. Study selection process.Table 2 with forest plots by region in Fig. 2. Adherence
was estimated at 62% (95% CI, 57–68; I2, 97%) overall
and this varied by region as summarized in the Table 2; it
was lowest in North America (53%) and highest in Africa
and Asia (84%). There was considerable heterogeneity
between studies as shown by large I2 values. We used
meta-regression to examine the impact of continent,
adherence measure, adherence threshold (100%, 95%,
90%, 85%), sex (<50% or 50% women), age group
(<20 or 20 years old) and study year (before 2005 or
after/including 2005) on this heterogeneity (Table 3);
however, none of the variables fully explained the
between-study heterogeneity.
Studies conducted after 2005 showed higher adherence
rate (74%) than conducted pre-2005 (59%). The majority
(98%) of the studies used either viral suppression (n¼ 36)
or self-report (n¼ 13) as the adherence measure. Other
measurements included pharmacy refills. Nine American
studies measured adherence by self-report, but only two
South American, one Asian study and one African study
measured using self-report. On the contrary, viral
suppression was a more common form of measurement
outside North America, with 13 of 22 studies in North
America, all 12 in Europe, three of five in South America,
six of eight in Africa and two of three in Asia. Nine studies
had multiple measures.
In order to assess whether the measure of adherence used
by the different studies had an impact on the prevalence of
adolescent adherence, we ran additional and separate
meta-analyses for those studies that had viral suppressionhorized reproduction of this article is prohibited.
3 additional records identified through
bibliographic search 
436 records excluded
151 of full-text articles excluded
No relevant data (n = 69)
Inappropriate study design (n = 39)
Inappropriate age group (n = 21)
Unrepresentative population (n =11)
No original data (n = 6)
Duplicate study population (n = 5) 
32 records excluded due to
language restriction  
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited
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Table 2. Percentage adherence by subgroups.
Number of studies % adherence 95% CI
Overall 50 62.3 57.1–67.6
North America 22 52.7 46.5–59.0
Africa 8 83.8 78.9–88.7
Asia 3 83.9 76.8–91.0
Europe 12 62.0 50.7–73.3
South America 5 62.8 46.6–77.0
Sex
50% female 27 65.6 58.8–72.4
<50% female 15 54.3 45.9–62.7
Age
Adolescents [12–29] 34 60.1 53.3–67.0
Young adults [20–24] 10 67.9 58.6–77.3
Study year
Before 2005 22 59.3 49.2–69.4
2005 onwards 16 77.0 72.0–82.0
Adherence measurea
Viral load 36 62.2 56.0–68.4
Self-report 20 59.1 51.8–66.4
CI, confidence interval. If viral load (VL) is taken as the primary measure, adherence is
as follows. VL 62% (95% CI 56–68), self-report 62 (95% CI 53–71) and pill count 72
(95% CI 60–84).
aPublications with multiple measures were included in this subgroup analysis.as the marker for sufficient adherence and those that used
self-report, regardless of the level of either of these
measures. Viral suppression was used as a measure of
adherence in 36 studies while self-report was solely or
additionally measured in 19 studies. Overall, the
prevalence of adherence when using viral suppression
as a proxy for complete adherence was 62.2% (95% CI,
56.0–68.4) was comparable to the estimate provided self-
report of 59.1% (95% CI 51.8–66.4%), which showed
that the measure of adherence has a little effect on the
adherence estimates as they are in agreement.Discussion
The findings from this systematic review and meta-
analysis showed that overall, from studies globally, 62% of
adolescents and young adults were adherent to ART (as
defined by >85%, 90%, 95%, 100%) during the time
defined by the study or through viral suppression. There
were differences between regions with lower adherence
in Europe, South America and North America and
higher levels in Africa and in Asia. There are no other
global estimates of adherence in this group, although a
meta-analysis of North American studies by Reisner and
Mimiaga [2] reported rates between 28.3 and 69.8%. We
have updated these figures by adding 13 additional studies
in North America that were published after this review,
which showed similarly disparate results (28.0–74.5%).
Geographic variation in adherence has also been reported
for adults. Mills et al. [74] carried out a meta-analysis of
adult adherence to ARTand found similar estimates both
overall [64% (95% CI, 59–70; I2, 99%)] and by region:
they estimated adherence at 55% (95% CI, 49–62)
amongst adults in North America and 77% (95% CI, 68–
85) in Africa, similar to our findings of 53 and 84%,
respectively. They did not include studies from other
regions.pyright © Lippincott Williams & Wilkins. UnauthoIn contrast, our results suggest lower adherence in
adolescents than adults for Europe; a multicentre prospec-
tive cohort study in 17European countrieswith 1323 adult
patients [75] showed 80% of its population achieving
virological suppression (95% CI, 78–82), significantly
higher than our adolescent estimate of 62% (95% CI,
51–73). Similarly, aBrazilian studywith 1972 adult patients
[76]with 75%of the study population achievingmore than
95% adherence (95% CI, 73–77) is also higher than the
adolescent population estimate for South America of
63% (95% CI, 47–77). There are fewer studies in Asian
adultsor adolescents: a studyof 149Thai adults showed77%
adherence (95% CI, 71–84) [77], comparable to the 83%
(95% CI, 77–89) we found in adolescents.
Thus, in comparison with the adult levels, we have found
lower adherence in adolescents in Europe and South
America, while in North America and Africa and possibly
Asia levels are comparable to adults. This is unanticipated
given that many studies comparing viral suppression
between adolescents and adults showed that adolescents
are less likely to achieve viral suppression than the adult
population [31,33,78,79]. Possible reasons could be either
a selection from African, North American and Asian
studies, as individuals enrolled in a study aremore likely to
be those who are more engaged in care, or a real
difference due to variation in the meaning and experience
of adolescence in different settings. It may be that in
Africa and Asia, the population enrolled in the study have
little differences than the adult population in the same
setting culturally and socially, especially when they are a
bit older (16–24 years). They are likely to have already
worked and may have children of their own, compared
with the adolescent population in Europe and South
America where there are bigger differences in the adult
and adolescent age groups.
The regional disparity in adherence, now documented in
adults and adolescents, may reflect the significant
differences in the healthcare systems between North
America and Africa [5,80] and the different HIV
epidemic, with Africa having a generalized epidemic in
comparison with a focused epidemic in North America
and Europe [5,81]. This observation is most likely
multifactorial, but probably reflects the communities
most affected by HIVas well as the different funding and
accessibility of the healthcare services. For instance, in
resource-poor regions with generalized epidemics, HIV
testing and ART provision are widespread and can
include house to house testing and care. In addition, it is
usually free for eligible individuals [82] whilst in North
America and Europe the HIV epidemic remains focused
often being ‘hidden’ amongst certain vulnerable, core risk
groups with less access to healthcare despite dispropor-
tionally richer resources [6]. The latest figures from
North America show a high prevalence and incidence
rates amongst MSMAYA of African and Hispanic descent
[83], a group typically marginalized outside of healthcarerized reproduction of this article is prohibited.
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Fig. 2. Pooled proportion of patients adhering to antiretroviral therapy by global region. (a) North America, (b) Africa.provision with high rates of incarceration, which is also
linked with poor ART adherence [84]. In the UK, a
disproportionate number of ‘late presenters’ to healthcare
come from Black African communities [85].Copyright © Lippincott Williams & Wilkins. UnautFurthermore, in sub-Saharan Africa where HIV inci-
dence and prevalence globally is highest, AYAwomen are
likely to become pregnant in the second decade of life
[86]. In order to achieve the IAS goals of an HIV-freehorized reproduction of this article is prohibited.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Table 3. Odds ratios from meta-regression results of all studies
(nU50).
Univariate analysis
Category n Studies OR (95% CI) P
No covariate
Sex 50% female 27 1
<50% female 15 0 6 (0.4–1.1) 0.13
Continent North America 22 1
Africa 8 2.3 (1.1–5.0) 0.04
Asia 3 0.8 (0.3–2.8) 0.78
Europe 12 1.7 (0.9–3.3) 0.11
South America 5 1.8 (0.7–4.6) 0.24
Age 12–19 34 1
20–25 10 0.73 (0.4–1.4) 0.35
Study year Pre-2005 16 1
2005 onwards 22 2.4 (1.3–4.4) <0.01
Adherence
measure
Viral suppression 36 1
Self-report 13 0.9 (0.5–1.7) 0.74
Pill count 1 1.9 (0.3–13.4) 0.50
Adherence
thresholds
100% 11 1
95% 4 1.7 (0.7–3.7) 0.21
90% 8 0.9 (0.3–2.5) 0.84
85% 2 2.6 (0.7–9.4) 0.13
CI, confidence interval; OR, odds ratio.generation, prevention of mother-to-child-transmission
through ART and adherence is critical and AYA-focused
appropriate care needs to be reflected in ART delivery
and retention programmes.
Our study found that studies that were conducted from
2005 onwards showed higher adherence rate (74%)
than studies conducted before 2005 (59%). This is
consistent with the fact that in earlier studies, the
participants would have had more complicated treatment
regimes, higher pill burden and experienced greater
toxicity from ARTand thus are more likely to have been
nonadherent to treatment.
The strengths of this systematic review include explicit
eligibility criteria, conduct of a comprehensive search and
the usage of random-effects model to pool proportions in
keeping with the large heterogeneity. Themain limitation
is in the quality of the studies. Accurate measurement of
adherence has been a challenge to researchers and there is
little consistency in adherence classification [87]. Patient
recall and pill counts have inherent biases in their
measurement [88] such as self-enhancement bias and
recall bias, in addition how representative individuals
who enrol into adherence studies are of the general
populations from which they are drawn in unknown.
Furthermore, as studies included were observational
studies, some heterogeneity may have been introduced to
our study due the lack of standardisation and variations in
measuring adherence despite no significant differences
between the measures of adherence and the thresholds for
adherence were shown in the meta-regression (Table 1).
With such high levels of heterogeneity in this study, the
results should be interpreted with caution.
Due to the paucity of longitudinal studies, our study only
looked at the cross-sectional adherence data, meaningCopyright © Lippincott Williams & Wilkins. Unautthat we were unable to explore the sustainability and
dynamics of adherence. Also, the heterogeneity of the
information offered by individual studies meant that we
were unable to examine the effect of adherence patterns,
missed doses and treatment interruptions despite the
possibility of these factors having a big impact on the
treatment outcome such as immunological recovery and
viral resistance to ART and these events tend to occur
more frequently amongst AYA [89]. Furthermore, due to
the nature of the studies, as with all meta-analyses of
published data, we are not able to include data from AYA
who, choose not to initiate medication despite eligibility,
became lost to follow up or chose not to enrol into a
study, or those deemed inappropriate for treatment by
their physicians. Information on numerous contributing
factors such as incentives and counselling as well as
broader contextual factors such as political or socio-
demographic status were not available in many studies
that may have confounded the adherence level. However,
although assessing the impact of all of the possible factors
would be informative, it does not change the finding that
nearly half of all HIV positive AYA population have
suboptimal adherence rates that risks the development of
drug resistance, disease progression and transmission
to others.
The literature search did not yield studies from Australasia
and only three studies from Asia. Moreover, countries
such as Brazil, South Africa and United States were
overrepresented meaning that these results may reflect
adherence rates overall. Finally, there is a possibility that
this review has missed articles (unpublished) despite
extensive searching, and the restriction to English
language may have excluded key data.
Our findings have important implications. Although we
were unable to take into account all the possible factors
such as drug regimens and adherence dynamics that may
affect the overall adherence, we have shown that almost
40% of adolescents with HIV who are eligible for and
have started ART are nonadherent to treatment and this
level of nonadherence requires action. These data are
from a period before recent changes to national guidelines
and WHO recommendations that expand eligibility and
would initiate treatment at an earlier point in the disease.
We assume that the poor reported adherence is highly
contextual and multifactorial, but on an individual level,
healthcare and public health providers need to proactively
engage with AYA to enhance adherence to ART for this
vulnerable group. On a policy level, in areas where AYA
ART adherence is lower than that of adults (South
America and Europe as shown by this study), programmes
with better understanding of culturally specific barriers to
HIV medication targeting this age group may have the
largest potential impact on future health and incidence of
HIV. However, in Africa and Asia, where adherence
levels in adolescents are relatively high, the exclusion ofhorized reproduction of this article is prohibited.
Co
1954 AIDS 2014, Vol 28 No 13high-risk youth from ART may risk preventing
potentially adherent patients from lifesaving treatment
[34], and although increasing the scale-up of ART
coverage in Africa may be beneficial to all, it is critical to
enhance access to AYA.
Provision of successful HIV care requires a test and
treatment cascade with a potential for drop off at many
levels [89,90] and linkage for re-engagement must be
offered at every step [91] in order to retest those at risk,
and support sustained adherence and retention. Although
this analysis focuses only on the latter part of the cascade
and only at a single time-point, it has shed light on key
gaps in services that could better support AYA living with
HIV. In particular, the wide discrepancy in reported
adherence between HIV-positive AYA the different
continents requires urgent action, especially in resourced
settings wherein the delivery of services needs to be
appropriately refocused.Acknowledgements
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